ResMed
RMD
225.98
+5.29
+2.40%
ResMed
US · RMD
#644 by market cap
Listed 1970
225.98
+5.29
+2.40%
Live - 5344 symbols - heartbeat 127s ago
· 2026-10-08 03:31
After-hours
225.98
0.00%
Overnight
224.90
-0.48%
- Market cap
- 31.78B
- P/E (TTM)i
- 21.67
- P/Bi
- 4.83
- EPSi
- 10.43
- Div yieldi
- 1.06%
- 52W posi
- 48%
Reader sentiment
Are you bullish or bearish on RMD?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 10.87, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +9.85% YoY
Margins
- Gross margin
- 61.06%
- Operating margin
- 33.76%
- Net margin
- 26.94%
Key ratios & quality
- Enterprise valuei
- 31.00B
- PEG ratioi
- 1.12
- Altman Z-Scorei
- 10.87
PEG uses trailing P/E against the 3-year net income growth rate (19.28%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.61B | 2.96B | 3.20B | 3.58B | 4.22B | 4.69B | 5.15B | 5.65B |
| Gross profit | 1.49B | 1.72B | 1.84B | 2.02B | 2.36B | 2.66B | 3.05B | 3.45B |
| Selling & admin expenses | 645.01M | 676.69M | 670.39M | 737.51M | 874.00M | 917.14M | 993.05M | 1.12B |
| Research & development | 180.65M | 201.95M | 225.28M | 253.58M | 287.64M | 307.53M | 331.28M | 378.29M |
| Operating profit | 635.99M | 809.06M | 912.35M | 1.00B | 1.15B | 1.38B | 1.69B | 1.91B |
| Pretax profit | 518.85M | 733.09M | 883.66M | 960.48M | 1.10B | 1.26B | 1.68B | 1.92B |
| Tax | 114.26M | 111.41M | 409.16M | 181.05M | 204.11M | 243.85M | 276.84M | 396.12M |
| Net profit | 404.59M | 621.67M | 474.51M | 779.44M | 897.56M | 1.02B | 1.40B | 1.52B |
| Basic EPS | 3 | 4 | 3 | 5 | 6 | 7 | 10 | 10 |
| Diluted EPS | 2.80 | 4.27 | 3.24 | 5.30 | 6.09 | 6.92 | 9.51 | 10.43 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 1.29B | 1.35B | 1.34B | 1.42B | 1.43B | 1.46B |
| Gross profit | 766.41M | 820.07M | 820.82M | 878.72M | 890.98M | 861.22M |
| Selling & admin expenses | 245.30M | 267.16M | 259.19M | 278.40M | 285.66M | 296.28M |
| Research & development | 83.94M | 86.44M | 87.32M | 90.97M | 94.27M | 105.73M |
| Operating profit | 426.27M | 454.54M | 462.35M | 497.60M | 499.81M | 448.71M |
| Pretax profit | 417.69M | 458.05M | 446.79M | 496.15M | 502.31M | 474.16M |
| Tax | 52.65M | 78.35M | 98.26M | 103.56M | 103.58M | 90.73M |
| Net profit | 365.04M | 379.71M | 348.54M | 392.59M | 398.73M | 383.43M |
| Basic EPS | 2 | 3 | 2 | 3 | 3 | 3 |
| Diluted EPS | 2.48 | 2.58 | 2.37 | 2.68 | 2.74 | 2.64 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 1.15B | 1.52B | 1.57B | 1.93B | 2.37B | 2.36B | 3.51B | 4.32B |
| Cash & ST investments | 147.13M | 463.16M | 295.28M | 273.71M | 227.89M | 238.36M | 1.21B | 1.47B |
| Inventory | 349.64M | 416.92M | 457.03M | 743.91M | 998.01M | 822.25M | 927.71M | 945.81M |
| Total assets | 4.11B | 4.59B | 4.73B | 5.10B | 6.75B | 6.87B | 8.17B | 8.97B |
| Total current liabilities | 555.99M | 602.76M | 911.77M | 689.30M | 758.53M | 910.66M | 1.02B | 1.40B |
| Short-term debt | 11.99M | 33.25M | 35.59M | 31.77M | 31.82M | 35.18M | 40.41M | 289.09M |
| Long-term debt | 1.26B | 1.16B | 643.35M | 765.33M | 1.43B | 697.31M | 658.39M | 399.42M |
| Total liabilities | 2,035,489,000.00 | 2,090,349,000.00 | 1,842,446,000.00 | 1,735,102,000.00 | 2,621,805,000.00 | 2,008,351,000.00 | 2,206,532,000.00 | 2,380,557,000.00 |
| Total equity | 2.07B | 2.50B | 2.89B | 3.36B | 4.13B | 4.86B | 5.97B | 6.59B |
| Retained earnings | 2.44B | 2.83B | 3.08B | 3.61B | 4.25B | 4.99B | 6.08B | 7.26B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 3.21B | 3.51B | 3.63B | 3.82B | 4.06B | 4.32B |
| Cash & ST investments | 932.71M | 1.21B | 1.38B | 1.42B | 1.66B | 1.47B |
| Inventory | 862.64M | 927.71M | 945.81M | 922.05M | 911.88M | 945.81M |
| Total assets | 7.57B | 8.17B | 8.31B | 8.50B | 8.78B | 8.97B |
| Total current liabilities | 940.52M | 1.02B | 1.26B | 1.25B | 1.35B | 1.40B |
| Short-term debt | 38.66M | 40.41M | 289.87M | 289.67M | 289.16M | 289.09M |
| Long-term debt | 663.13M | 658.39M | 408.66M | 403.92M | 404.17M | 399.42M |
| Total liabilities | 2,020,689,000.00 | 2,206,532,000.00 | 2,187,088,000.00 | 2,182,491,000.00 | 2,292,374,000.00 | 2,380,557,000.00 |
| Total equity | 5.55B | 5.97B | 6.12B | 6.32B | 6.49B | 6.59B |
| Retained earnings | 5.78B | 6.08B | 6.34B | 6.65B | 6.96B | 7.26B |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 459.05M | 802.26M | 736.72M | 351.15M | 693.30M | 1.40B | 1.75B | 1.81B |
| Depreciation & amortization | 150.80M | 181.37M | 191.52M | 193.84M | 197.56M | 216.21M | 235.81M | 244.15M |
| Free cash flow | 381.71M | 696.32M | 619.89M | 195.11M | 559.30M | 1.29B | 1.65B | 1.63B |
| Dividends paid | -211.71M | -225.09M | -226.71M | -245.34M | -258.28M | -282.32M | -310.88M | -349.66M |
| Stock buybacks / issuance | 13.88M | 48.18M | 37.79M | 47.38M | 49.14M | -96.92M | -225.59M | -625.53M |
| Ending cash balance | 147.13M | 463.16M | 295.28M | 273.71M | 227.89M | 238.36M | 1.21B | 1.47B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 578.66M | 538.77M | 457.32M | 339.75M | 554.13M | 454.63M |
| Depreciation & amortization | 51.91M | 74.29M | 57.67M | 62.33M | 69.03M | 55.12M |
| Free cash flow | 554.87M | 504.99M | 411.54M | 305.19M | 514.54M | 397.38M |
| Dividends paid | -77.70M | -77.59M | -87.75M | -87.58M | -87.24M | -87.09M |
| Stock buybacks / issuance | -66.00M | -69.85M | -141.81M | -145.46M | -167.59M | -170.69M |
| Ending cash balance | 932.71M | 1.21B | 1.38B | 1.42B | 1.66B | 1.47B |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 19.59 | 27.21 | 17.63 | 24.96 | 23.96 | 22.70 | 25.86 | 24.27 |
| ROA %i | 11.28 | 14.30 | 10.19 | 15.87 | 15.15 | 14.99 | 18.62 | 17.77 |
| ROIC %i | 15.17 | 18.35 | 13.16 | 19.59 | 17.97 | 18.48 | 22.31 | 21.41 |
| 5-year avg ROE %i | 19.32 | 20.54 | 19.77 | 21.02 | 22.67 | 23.29 | 23.02 | 24.35 |
| EBIT margin %i | 21.29 | 26.16 | 28.39 | 27.96 | 27.28 | 27.97 | 32.79 | 33.76 |
| FCF / sales %i | 14.64 | 23.55 | 19.39 | 5.45 | 13.24 | 27.46 | 32.08 | 28.81 |
| Current ratioi | 2.06 | 2.53 | 1.73 | 2.80 | 3.12 | 2.59 | 3.44 | 3.10 |
| Quick ratioi | 1.22 | 1.56 | 1.00 | 1.23 | 1.23 | 1.22 | 2.16 | 1.83 |
| Debt / assetsi | 30.94 | 28.32 | 16.79 | 18.01 | 23.40 | 12.72 | 10.42 | 9.21 |
| LT debt / equityi | 60.75 | 50.70 | 26.27 | 26.36 | 37.48 | 17.24 | 13.60 | 8.15 |
| Interest coveragei | 15.35 | 19.16 | 37.84 | -- | -- | 28.67 | -- | -- |
| Revenue CAGR (3Y) %i | 12.34 | 12.68 | 10.96 | 11.14 | 12.61 | 13.59 | 12.88 | 10.21 |
| Net income CAGR (3Y) %i | 4.71 | 22.01 | 14.56 | 24.43 | 13.02 | 29.10 | 21.58 | 19.28 |
| FCF CAGR (3Y) %i | -7.36 | 26.67 | 12.66 | -20.04 | -7.04 | 27.55 | 103.77 | 42.80 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 25.81 | 25.86 | 25.41 | 25.68 | 25.25 | 24.27 |
| ROA %i | 18.26 | 18.62 | 18.52 | 19.00 | 18.59 | 17.77 |
| ROIC %i | 21.56 | 22.31 | 22.10 | 22.41 | 22.15 | 21.41 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 30.64 | 32.79 | 33.52 | 34.14 | 34.60 | 33.76 |
| FCF / sales %i | 31.06 | 32.08 | 33.41 | 32.91 | 31.35 | 28.81 |
| Current ratioi | 3.41 | 3.44 | 2.89 | 3.06 | 3.01 | 3.10 |
| Quick ratioi | 1.99 | 2.16 | 1.87 | 1.97 | 2.00 | 1.83 |
| Debt / assetsi | 11.10 | 10.42 | 10.19 | 9.97 | 9.60 | 9.21 |
| LT debt / equityi | 14.44 | 13.60 | 9.09 | 8.83 | 8.53 | 8.15 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Sleep and Breathing Health is the largest reported line at 88.05% of revenue, across 2 reported segments.
- The next-largest line, Residential Care Software, is a distant second at 11.95% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Sleep and Breathing Health88.05%
Residential Care Software11.95%
Region
United States63.01%
Rest of the World36.99%
Quote time 2026-10-08 03:31:56 · For reference only, not investment advice and not tailored to your situation.